Qadri S M, Halim M A, Ueno Y, Abumustafa F M, Postle A G
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Chemotherapy. 1995 Jul-Aug;41(4):253-6. doi: 10.1159/000239353.
In vitro antibacterial activity of the new macrolide azithromycin was tested against 116 strains of Brucella melitensis, isolated from 115 patients in a major tertiary care referral center. Eighty-seven percent of the strains were inhibited by 1.0 mg/l and all the 116 strains by 2.0 mg/l of azithromycin. Comparison was made with tetracycline, gentamicin, trimethoprim-sulfamethoxazole, rifampicin and ciprofloxacin. All the isolates were susceptible to gentamicin, tetracycline, trimethoprim-sulfamethoxazole, rifampicin. One hundred and fifteen of the 115 strains were also susceptible to ciprofloxacin.
对从一家大型三级医疗转诊中心的115名患者中分离出的116株羊种布鲁氏菌，测试了新型大环内酯类药物阿奇霉素的体外抗菌活性。87%的菌株被1.0毫克/升的阿奇霉素抑制，所有116株菌株被2.0毫克/升的阿奇霉素抑制。并与四环素、庆大霉素、甲氧苄啶-磺胺甲恶唑、利福平及环丙沙星进行了比较。所有分离株对庆大霉素、四环素、甲氧苄啶-磺胺甲恶唑、利福平敏感。115株菌株中的115株对环丙沙星也敏感。
